Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03662984
Other study ID # NL.ABR.65583
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 1, 2018
Est. completion date November 13, 2020

Study information

Verified date January 2021
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Free fatty acids (FFA) are the main fuel source in a healthy adult heart, since they are responsible for 70-80% of the myocardial ATP production. Plasma FFA and triglycerides (TG) levels are elevated in obesity and diabetes, evoking substrate competition in the heart: the increased availability of lipids will lead to fat accumulation in the heart, which is associated with cardiac insulin resistance and will therefore restrain insulin-stimulated cardiac glucose oxidation. It is shown that a lower myocardial glucose uptake correlates with decreased diastolic function. The benefits of counterbalancing this lipid overload is proven by previous research in pre-diabetes, which showed the reversibility of impaired myocardial substrate metabolism and improvement of function and structure after modest weight loss induced by lifestyle changes. Ciprofibrates are a ligand of the peroxisome proliferator-activated receptor (PPAR) α and are considered to be a major regulator of the lipid metabolism and promote fat oxidative capacity. They are not only effective in normalizing lipid-lipoprotein levels in patients with the metabolic syndrome, but improve also their insulin sensitivity. We therefore hypothesize that ciprofibrate administration in subjects with impaired glucose metabolism (IGM) influence the myocardial substrate metabolism (via the PPARα pathway) and thereby improve myocardial insulin sensivity.


Description:

Objectives: The main objective of the study is to investigate whether ciprofibrate treatment can improve myocardial insulin sensitivity in subjects with IGM. As secondary objectives we want to investigate whether ciprofibrate treatment also improves diastolic and myocardial mitochondrial function and decreases intracardiomyocellular lipid content. Futhermore, since ciprofibrate could also affect cardiac metabolism indirectly, we want to investigate the effect of ciprofibrate on skeletal and hepatic glucose uptake, hepatic lipid storage and composition. Study design: In a randomized, double-blind, cross-over design, the effects of ciprofibrate supplementation on myocardial insulin sensitivity will be compared to placebo in humans with IGM. Study population: Twelve male, overweight (BMI > 27 kg/m2), insulin-resistant subjects, aged between 40 and 70 years, without cardiac disease, will participate in this study. Intervention: Subjects will be asked to take one pill of ciprofibrate 100mg, or placebo, once daily (at dinner), for 35 days. Main study parameters/endpoints: The main study endpoint is the difference in myocardial insulin sensitivity (measurement of glucose uptake using radio-active labeled 18F-FDG tracer in PET-MRI) after ciprofibrate administration compared to the placebo trial.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date November 13, 2020
Est. primary completion date November 6, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Race: caucasian - Sex: male - Age: 40-70 years - BMI: 27-35 kg/m2 - Stable dietary habits: no weight gain or loss > 5kg in the last three months - Insulin resistant: glucose clearance rate below < 360 ml/kg/min, as determined using OGIS120 Exclusion Criteria: - Patients with a cardiac disease or with instable angina - Patients with hepatic or renal failure - Haemoglobin <7.8 mmol/l - In case of an abnormal ECG in rest: this will be discussed with the responsible medical doctor - HbA1c > 6.5% - Diagnosed with type 1 or type 2 diabetes mellitus - Patients with alcohol abuse - Use of a fibrate - Medication use known to interfere with glucose homeostasis/metabolism - Use of anti-coagulants, excluding platelet aggregation inhibitors - Subjects who do not want to be informed about unexpected medical findings during the screening /study, or do not wish that their physician is informed, cannot participate in the study. - Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the intervention. - Participation in another biomedical study within 1 month before the first screening visit - Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk - Any contra-indication to MRI scanning. These contra-indications include patients with following devices: - Electronic implants such as pacemakers or defibrillator or neurostimulator - Central nervous system aneurysm clip - Some hearing aids (such as cochlear implant) and artificial (heart) valves which are contraindicated for MRS - Iron containing corpora aliena in the eye or brains - Claustrophobia - Participation in earlier research or medical examinations in the past 3 months that included PET/MRI scanning

Study Design


Intervention

Drug:
Ciprofibrate 100Mg Tablet
Ciprofibrate is a PPARa ligand and is considered to be a major regulator of the lipid metabolism. PPARa regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARa in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
Placebo Oral Tablet
To compare ciprofibrate

Locations

Country Name City State
Netherlands Nutrition and Movement Sciences Maastricht Limburg

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center Maastricht University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Myocardial insulin sensitivity measured by the insulin-stimulated myocardial glucose uptake by FDG-PET 1hour, day 35
Secondary Hepatic glucose uptake measured by the insulin-stimulated myocardial glucose uptake by FDG-PET 1hour, day 35
Secondary Skeletal muscle glucose uptake measured by the insulin-stimulated myocardial glucose uptake by FDG-PET 1hour, day 35
Secondary Brown adipose tissue (BAT) glucose uptake measured by the insulin-stimulated myocardial glucose uptake by FDG-PET 1hour, day 35
Secondary Insulin sensitivity Glucose infusion rate (GIR) from the hyperinsulinemic euglycemic clamp 4hours, day 35
Secondary Intracardiomyocellular lipid content Cardiac 1H-MRS: fasted & insulin-stimulated 1hour, day 35
Secondary Cardiac systolic function Functional cardiac MRI: fasted & insulin-stimulated 1hour, day 35
Secondary In vivo myocardial mitochondrial function (PCr/ATP ratio) Cardiac 31P-MRS: fasted 1hour, day 28
Secondary Cardiac diastolic function Cardiac ultrasound 1hour, day 34
Secondary Intrahepatic lipid content and hepatic lipid composition Hepatic 1H-MRS: fasted 1hour, day 28
Secondary Blood pressure 24-hour blood pressure monitor 24hours, day 27
Secondary Whole body (sleeping) energy metabolism (sleeping energy expenditure and substrate oxidation) Respiration chamber: overnight 12 hours, day 34
Secondary Whole body maximum aerobic capacity VO2 max test 1hour, day 28
Secondary Total body mass and fat mass Body composition 0.5 hour, day 35
Secondary Ex vivo PPARalpha expression and downstream targets Skeletal muscle biopsy 0.5 hour, day 35
Secondary Postprandial lipid response Meal test 5hour, day 34
Secondary Anti-inflammatory effects (in the long term on the immune cells; acute effect on postprandial response), circadian rhythm PBMC 6hour, day 0-34-35
Secondary Cholesterol profile Blood after venapunction 5hours, day 0,7,14,21,28,35
See also
  Status Clinical Trial Phase
Recruiting NCT04558450 - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) N/A
Recruiting NCT02499601 - CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD) N/A
Completed NCT01775865 - Targeting Inflammation to Treat Cardiovascular Aging Phase 2
Terminated NCT01188369 - Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy Phase 4
Recruiting NCT05552521 - Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants
Recruiting NCT05438030 - Diastolic Function Assessment With Cardiac Magnetic Resonance Imaging N/A
Completed NCT04128735 - Diastolic Dysfunction in Morbidly Obese Patients Undergo Bariatric Surgery
Completed NCT00689819 - Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients N/A
Recruiting NCT04149990 - Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI Phase 2
Completed NCT03768752 - Diastolic Dysfunction and Interstitial Lung Edema in Septic Patients
Completed NCT02932436 - Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics Phase 4
Recruiting NCT05847244 - The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction Phase 2
Enrolling by invitation NCT04190420 - The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study
Completed NCT04114474 - Pre-operative Focused Transthoracic Echocardiography for Prediction of Post-operative Cardiac Complications
Not yet recruiting NCT06131008 - Diastology-Guided Management of Decompensated Heart Failure N/A
Completed NCT03110614 - Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of COPD
Not yet recruiting NCT02285309 - Perioperative Measurements of Diastolic Function in Cardiac Surgery N/A
Completed NCT01761318 - Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Phase 4
Completed NCT00804518 - Effect of Exercise on Heart Function in Healthy Elderly People N/A
Completed NCT00907439 - Study of the Effect of Inhaled Anesthetics on Diastolic Heart Function Using a Doppler-derived Efficiency Index N/A